“…Importantly, mesenchymal CTCs allowed a more accurate prediction of prognosis than the expression of epithelial markers alone [4] . Clinical significance of mesenchymal CTCs was examined not only in BC, but also in other cancers, including colorectal [43,132] , hepatocellular [133,134] , gastric [135] , prostate [41,136] , bladder [137] , ovarian [138] , endometrial [139] , and non-small cell lung cancer [140] . The majority of data concern the metastatic setting.…”